2. Search Result
Search Result
Pathways Recommended: Antibody-drug Conjugate/ADC Related
Results for "

Drug candidate

" in MedChemExpress (MCE) Product Catalog:

28

Inhibitors & Agonists

3

Screening Libraries

3

Biochemical Assay Reagents

2

Peptides

2

Natural
Products

1

Oligonucleotides

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-76772A
    (+)-Cevimeline hydrochloride hemihydrate

    (+)-SNI-2011; (+)-AF102B hydrochloride hemihydrate

    		 mAChR Neurological Disease
    (+)-Cevimeline hydrochloride hemihydrate ((+)-SNI-2011), a potent muscarinic receptor agonist, is a candidate therapeutic drug for xerostomia in Sjogren's syndrome.
    (+)-Cevimeline hydrochloride hemihydrate
  • HY-76772B
    (-)-Cevimeline hydrochloride hemihydrate

    (-)-SNI-2011; (-)-AF102B hydrochloride hemihydrate

    		 mAChR Neurological Disease
    (-)-Cevimeline hydrochloride hemihydrate ((-)-SNI-2011), a novel muscarinic receptor agonist, is a candidate therapeutic drug for xerostomia in Sjogren's syndrome.
    (-)-Cevimeline hydrochloride hemihydrate
  • HY-157403
    Jun12682

    		Virus Protease SARS-CoV Infection
    Jun12682 is an orally active SARS-CoV-2 papain-like protease (PL pro) inhibitor, with a Ki value of 37.7 nM and an EC50 value of 1.1 μM in the FlipGFP PL pro assay. Jun12682 has efficacy in hindering PL pro both deubiquitination and deISGylation, with Ki values of 63.5 and 38.5 nM, respectively. Jun12682 exhibits resistance in multiple PL pro mutant strains, and its enzymatic activity is comparable to that of the wild-type. Jun12682 can be used for the study of the SARS-CoV-2 .
    Jun12682
  • HY-W087964
    Dodecanedioyl dichloride

    		Biochemical Assay Reagents Others
    Dodecanedioyl dichloride, Dodecanedioyl dichloride is commonly used in organic synthesis as a general building block for the preparation of various polymers and plastics, including nylon 12 and polyester resins, it can be used to introduce acid chloride groups into other organic molecules, which can then be further reaction to form more complex compounds, moreover, it has been used in medicinal chemistry as a starting material for the synthesis of various drugs and drug candidates.
    Dodecanedioyl dichloride
  • HY-132972
    TrxR-IN-2

    		TrxR Cancer
    TrxR-IN-2, a potential thioredoxin reductase (TrxR) inhibitor, represents a promising candidate drug for the chemoresearch of drug-resistant hepatocellular carcinoma.
    TrxR-IN-2
  • HY-16672
    AVX 13616

    		Bacterial Infection
    AVX 13616 shows the potent in vivo antibacterial activity of Avexa’s lead antibacterial candidate; particularly against drug-resistant Staphylococcus pathogens.
    AVX 13616
  • HY-161249
    Vanin-1-IN-4

    		Pantetheinase Inflammation/Immunology
    Vanin-1-IN-4 (compound (S)-1) is vanin-1 inhibitor with a chiral methyl substituent, with profils as potent drug-candidate but exist as an amorphous solid .
    Vanin-1-IN-4
  • HY-18332
    Amitifadine

    DOV-21947; EB-1010

    		 Serotonin Transporter Dopamine Transporter Dopamine Receptor Neurological Disease
    Amitifadine (DOV-21947) is an antidepressant drug candidate that functions as a triple reuptake inhibitor, targeting the reuptake of serotonin, norepinephrine, and dopamine, and has been shown to decrease binge drinking and alleviate negative emotions in animal models.
    Amitifadine
  • HY-162508
    KSK-104

    		Bacterial Infection
    KSK-104 has potent antibacterial activity against Mycobacterium tuberculosis (MIC=0.78 μM). The role of KSK-104 is mainly involved in the synthesis and recovery pathways of pyridoxal 5'-phosphate (PLP), PLP-dependent enzymes and oxidative stress networks. KSK-104, as a candidate molecule for novel anti-tuberculosis drugs, can be used to develop research against drug-resistant mycobacterium tuberculosis .
    KSK-104
  • HY-145829
    Tofacitinib Prodrug-1

    		JAK Apoptosis Inflammation/Immunology
    Tofacitinib precursor-1 is an effective and oral active precursor to mitigate the systemic adverse effects of Tofacitinib. Tofacitinib precursor-1 can effectively attenuate the oxazolone-induced colitis in mice model with low toxicity. Tofacitinib precursor-1 is a potential drug candidate for the research of ulcerative colitis .
    Tofacitinib Prodrug-1
  • HY-162462
    Antitumor agent-151

    		Apoptosis Cancer
    Antitumor agent-151 (7k) is a significant HsClpP agonist and an antileukemia drug candidate. Antitumor agent-151 (7k) exhibits remarkably enhanced proteolytic activity of HsClpP (EC50 = 0.79 μM) and antitumor activity in vitro (IC50 = 0.038 μM). Antitumor agent-151 (7k) induces apoptosis .
    Antitumor agent-151
  • HY-163546
    HSV-1-IN-1

    		HSV Infection
    HSV-1-IN-1 (compound 1b) is a drug candidate for herpes simplex virus HSV-1(IC50=0.5 nM) and HSV-2(IC50=16 nM) infection. HSV-1-IN-1 inhibits the helicase-primase complex to prevent viral replication, thereby inhibiting HSV infection .
    HSV-1-IN-1
  • HY-104086
    Cucurbit[7]uril
    1 Publications Verification

    CB7; Carrier CB7

    		 Biochemical Assay Reagents Others
    Cucurbit[7]uril is a cyclic organic molecule consisting of seven glycoluril units linked by methylene bridges. It has a rigid barrel-like structure with two identical inlets at both ends to selectively encapsulate guest molecules of appropriate size, shape, and polarity. Cucurbit[7]uril is known for its high binding affinity for a variety of organic and inorganic guests, including drugs, amino acids, peptides, and metal ions. This property makes them promising candidates for various applications in areas such as drug delivery, catalysis, and sensing.
    Cucurbit[7]uril
  • HY-153905
    Casein kinase 1δ-IN-6

    		Casein Kinase Neurological Disease
    Casein kinase 1δ-IN-6 is a potent and selective protein kinase CK-1δ inhibitor with an IC50 of 23 nM. Casein kinase 1δ-IN-6 shows neuroprotective and anti-inflammatory properties both in vitro and in vivo. Casein kinase 1δ-IN-6 is a promising drug candidate and can be used for neurodegenerative diseases research.
    Casein kinase 1δ-IN-6
  • HY-163030
    LasB-IN-1

    		Elastase NF-κB p38 MAPK Bacterial Infection Inflammation/Immunology
    LasB-IN-1 (compound 5f) is a potent and orally active inhibitor of LasB (IC50 = 8.7 μM). LasB-IN-1 effectively attenuates elastase production and biofilm formation by P. aeruginosa while alleviating the inflammatory response through downregulating MAPK and NF-κB pathways. LasB-IN-1 is potential to be a novel anti-infective candidate against drug-resistant infections .
    LasB-IN-1
  • HY-14266A
    Dapivirine hydrochloride

    		Apoptosis Reverse Transcriptase Autophagy HIV Infection
    Dapivirine hydrochloride is a non-nucleoside reverse transcriptase inhibitor with antitumor activity. Dapivirine hydrochloride attenuates the proliferation of glioblastoma cells and induces apoptosis. Dapivirine hydrochloride modulates autophagy and activates Akt, Bad, and SAPK/JNK signaling pathways. Dapivirine hydrochloride has shown inhibitory effects on glioma cell growth both in vitro and in vivo. Dapivirine hydrochloride is also a promising drug candidate for topical microbial agents for the prevention of sexual transmission of HIV-1 .
    Dapivirine hydrochloride
  • HY-149430
    YIAD-0205

    		Amyloid-β Neurological Disease
    YIAD-0205 is an orally available Aβ(1?42) aggregation inhibitor. YIAD-0205 demonstrated in vivo efficacy in an AD transgenic mouse model with five familial AD mutations (5XFAD) .
    YIAD-0205
  • HY-143702
    Fluorescent DOTAP

    NBD-DOTAP

    		 Fluorescent Dye Liposome Inflammation/Immunology Cancer
    Fluorescent DOTAP (NBD-DOTAP) is a cationic lipid which can be used for nucleic acid and protein delivery. Fluorescent DOTAP is labeled with a fluorophore NBD (maximum excitation/emission wavelength ∼463/536 nm). Fluorescent DOTAP can be used for gene delivery systems, drug delivery, as well as cell imaging and nanocarrier tracking. Fluorescent DOTAP is an ideal candidate for both biological and pharmaceutical formulation (e.g. co-delivery of vaccines) research .
    Fluorescent DOTAP
  • HY-172131
    Emoquine-1

    		Parasite Infection
    Emoquine-1 is an orally active and potent antimalarial drug. Emoquine-1 is efficient against multidrug-resistant Plasmodium parasites, including the Artemisinin-resistant quiescent stage. Emoquine-1 is active against proliferative P. falciparum with IC50 values of 20-55 nM. Emoquine-1 is a candidate to fight Plasmodium parasites resistant to artemisinin-based combination therapies (ACTs) with a capacity to eliminate persistent parasites .
    Emoquine-1
  • HY-16129A
    CBP-501 acetate

    		Calmodulin MAP3K MAPKAPK2 (MK2) Checkpoint Kinase (Chk) Cancer
    CBP-501 acetate, a cell-permeable calmodulin-binding peptide and a G2-abrogating drug candidate, inhibits the activity of multiple Ser 216-specific kinases, such as MAPKAP-K2, C-Tak1, CHK1 and CHK2, with IC50 values of 0.9 μM, 1.4 μM 3.4 μM and 6.5 μM, respectively. CBP-501 acetate is used for various types of cancer .
    CBP-501 acetate
  • HY-N7135
    Tropolone

    		Tyrosinase Fungal Metabolic Disease Inflammation/Immunology Cancer
    Tropolone is a seven-membered non-benzenoid aromatic compound, which is the precursor of many Azulene derivatives. Tropolone is a potent mushroom tyrosinase inhibitor with an IC50 value of 0.4 μM. Its inhibitory effect can be achieved by dialysis or excess CU 2+ Reversa. Tropolone exhibits broad anti-viral and anti-fungal activity and is synergistic upon co-treatment with nucleos(t)ide analog drugs. Tropolone is a promising candidate for research in osteosarcoma .
    Tropolone
  • HY-120181
    AGI-14100

    		Isocitrate Dehydrogenase (IDH) Cancer
    AGI-14100 is a metabolically stable and orally available mIDH1 inhibitor (IC50=6 nM). The pharmacochemical optimization of AGI-14100 is aimed at eliminating hPXR activation, resulting in the final drug candidate AG-120. AG-120 can be used in the study of cancers carrying IDH1 mutations. The discovery and development of AGI-14100 can be used for further studies of mutant isocitrate dehydrogenase 1 (mIDH1) inhibitors .
    AGI-14100
  • HY-124310
    PDE5-IN-6c

    		Phosphodiesterase (PDE) Neurological Disease
    PDE5-IN-6c is a potent and selective phosphodiesterase 5A1 (PDE5A1) inhibitor with the potential to inhibit Alzheimer's disease (AD). PDE5-IN-6c exhibits an excellent in vitro IC50 (0.056 nM), demonstrating its potent inhibitory activity. PDE5-IN-6c has improved water solubility, making it a more attractive drug candidate .
    PDE5-IN-6c
  • HY-N7135R
    Tropolone (Standard)

    		Tyrosinase Fungal Metabolic Disease Inflammation/Immunology Cancer
    Tropolone is a seven-membered non-benzenoid aromatic compound, which is the precursor of many Azulene derivatives. Tropolone is a potent mushroom tyrosinase inhibitor with an IC50 value of 0.4 μM. Its inhibitory effect can be achieved by dialysis or excess CU2+ Reversa. Tropolone exhibits broad anti-viral and anti-fungal activity and is synergistic upon co-treatment with nucleos(t)ide analog drugs. Tropolone is a promising candidate for research in osteosarcoma .
    Tropolone (Standard)
  • HY-16129
    CBP-501

    		Calmodulin Checkpoint Kinase (Chk) MAPKAPK2 (MK2) MAP3K Cancer
    CBP-501, a cell-permeable calmodulin-binding peptide and a G2-abrogating drug candidate, inhibits the activity of multiple Ser 216-specific kinases, such as MAPKAP-K2, C-Tak1, CHK1 and CHK2, with IC50 values of 0.9 μM, 1.4 μM 3.4 μM and 6.5 μM, respectively. CBP-501 is used for various types of cancer .
    CBP-501
  • HY-153519
    WWL0245

    		Epigenetic Reader Domain Cancer
    WWL0245 is a potent and seletive BRD4 PROTAC. WWL0245 selectively degrades BRD4 with sub-nanomolar DC50 (<1 nM) than BRD2/3 and PLK1 ( DC50>1 μM). WWL0245 shows excellent selective cytotoxicity in the BETi sensitive cancer cell lines, including AR-positive prostate cancer cell lines. WWL0245 is a promising drug candidate for AR-positive prostate cancer research and a valuable tool compound to study the biological function of BRD4 .
    WWL0245
  • HY-174867
    AY-4

    		PROTACs Ferroptosis Cancer
    AY-4 (Compound AY-4) is an efficient PROTAC degrader targeting FTH1 (Kd = 3.17 nM). AY-4 effectively upregulates the levels of ferrous (Fe 2+) and ferric (Fe 3+) ions in cells. AY-4 is a potential anticancer candidate compound that regulates iron homeostasis through ferritin degradation and enhances the efficacy of existing drugs. AY-4 can effectively reduce the level of FTH1 in breast cancer cells (Pink: FTH1 ligand AY-2 (HY-174871); Blue: E3 ligand Pomalidomide (HY-10984); Black: Linker, Pomalidomide-PEG3-acid (HY-174872)) .
    AY-4
  • HY-174802
    XL-3158

    		Cyclic GMP-AMP Synthase IKK IFNAR Inflammation/Immunology
    XL-3158 is a selective and cross-species Cyclic GMP-AMP synthase (cGAS) inhibitor (IC50: 11.1 μM for human cGAS, 2.19 μM for mouse cGAS). XL-3158 simultaneously occupy allosteric and orthosteric sites, stabilizing the activation loop in a closed, inactive conformation and thereby attenuating the cGAS-DNA interactions. XL-3158 inhibits cGAS by targeting phase separation. XL-3158 efficiently penetrates cells by inhibiting aggregate formation, effectively reducing the local concentration of cGAS within cells. XL-3158 has no obvious cytotoxicity within the effective concentration range and is suitable for subsequent cell function experiments. XL-3158 overcomes species selectivity barriers and serves as a drug candidate for cGAS-dependent inflammatory diseases.
    XL-3158

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: